In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Relay Therapeutics, Inc.

https://relaytx.com

Latest From Relay Therapeutics, Inc.

Finance Watch: Third Harmonic Launches The Largest IPO In Months

Biopharma stock prices overall are trending down again, but standout firms are raising cash, including the first company to price an IPO over $100m since May, Third Harmonic. Also, Sarepta and Alnylam launched large note offerings, totaling $1bn and $900m, respectively.

Financing Business Strategies

ESMO: Relay’s RLY-4008 Shows High Response, Lower Toxicity In Cholangiocarcinoma

The new data bolster the company’s hypothesis that more specific targeting of FGFR2 can overcome the toxicity limitations of other FGFR inhibitors.

Business Strategies Clinical Trials

Read-Outs To Look Out For At ESMO Cancer Congress

The European cancer congress returns in-person, with companies big and small presenting new agents and combinations across tumor types.

Commercial Companies

BridgeBio, BMS Set Sail In Expanded SHP2 Collaboration

Deal Snapshot: The licensing deal worth up to $905m is on top of the companies’ existing partnership to develop BBP-398 together with BMS’s PD-1 inhibitor Opdivo and shows growing pharma interest in SHP2.

Cancer Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • Allostery, Inc., ZebiAI
UsernamePublicRestriction

Register